Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients

Autor: Kada Klouche, Marion Morena, Bernard Canaud, Isabelle Jaussent, Leila Chenine, Hélène Leray-Moragues, Hélène Vernhet, Anne-Marie Dupuy, Jean-Paul Cristol, Anne-Sophie Bargnoux, Aurore Halkovich
Rok vydání: 2012
Předmět:
Male
Mineral Metabolism and the Kidney
lcsh:Medicine
Coronary Artery Disease
Cardiovascular
Gastroenterology
Diagnostic Radiology
Chronic Kidney Disease
Pathology
lcsh:Science
Aged
80 and over
education.field_of_study
Multidisciplinary
Calcinosis
Middle Aged
medicine.anatomical_structure
Nephrology
Biomarker (medicine)
Medicine
Female
Radiology
Research Article
musculoskeletal diseases
Adult
medicine.medical_specialty
Clinical Research Design
Population
Computed Tomography
Osteoprotegerin
Renal Dialysis
Vascular Biology
Diagnostic Medicine
Diabetes mellitus
Internal medicine
medicine
Vitamin D and neurology
Humans
cardiovascular diseases
education
Aged
business.industry
lcsh:R
nutritional and metabolic diseases
medicine.disease
Atherosclerosis
Coronary arteries
Fibroblast Growth Factors
Fibroblast Growth Factor-23
Endocrinology
Cross-Sectional Studies
Logistic Models
Kidney Failure
Chronic
lcsh:Q
business
Biomarkers
Calcification
Kidney disease
General Pathology
Zdroj: PLoS ONE
PLoS ONE, Vol 7, Iss 5, p e36175 (2012)
ISSN: 1932-6203
Popis: Background Osteoprotegerin (OPG) and fibroblast growth factor-23 (FGF23) are recognized as strong risk factors of vascular calcifications in non dialysis chronic kidney disease (ND-CKD) patients. The aim of this study was to investigate the relationships between FGF23, OPG, and coronary artery calcifications (CAC) in this population and to attempt identification of the most powerful biomarker of CAC: FGF23? OPG? Methodology/Principal Findings 195 ND-CKD patients (112 males/83 females, 70.8 [27.4–94.6] years) were enrolled in this cross-sectional study. All underwent chest multidetector computed tomography for CAC scoring. Vascular risk markers including FGF23 and OPG were measured. Logistic regression analyses were used to study the potential relationships between CAC and these markers. The fully adjusted-univariate analysis clearly showed high OPG (≥10.71 pmol/L) as the only variable significantly associated with moderate CAC ([100–400[) (OR = 2.73 [1.03;7.26]; p = 0.04). Such association failed to persist for CAC scoring higher than 400. Indeed, severe CAC was only associated with high phosphate fractional excretion (FEPO4) (≥38.71%) (OR = 5.47 [1.76;17.0]; p = 0.003) and high FGF23 (≥173.30 RU/mL) (OR = 5.40 [1.91;15.3]; p = 0.002). In addition, the risk to present severe CAC when FGF23 level was high was not significantly different when OPG was normal or high. Conversely, the risk to present moderate CAC when OPG level was high was not significantly different when FGF23 was normal or high. Conclusions Our results strongly suggest that OPG is associated to moderate CAC while FGF23 rather represents a biomarker of severe CAC in ND-CKD patients.
Databáze: OpenAIRE
Externí odkaz: